Leerink Partnrs Has Pessimistic Outlook of ALHC Q3 Earnings

Key Points

• Analysts at Leerink Partners have revised their Q3 2025 earnings per share (EPS) estimate for Alignment Healthcare down to ($0.08), reflecting a decline from the previous estimate of ($0.07).
• Alignment Healthcare reported a revenue of $1.02 billion for the last quarter, surpassing the projected $960.25 million, while its earnings per share was $0.07, beating consensus estimates.
• Alignment Healthcare's stock has recently experienced a decline of 5.9%, with a market cap of $2.57 billion and an average target price of $17.61 from analysts.

Alignment Healthcare, Inc. (NASDAQ:ALHC - Free Report) - Stock analysts at Leerink Partnrs dropped their Q3 2025 earnings estimates for shares of Alignment Healthcare in a research note issued on Wednesday, July 30th. Leerink Partnrs analyst W. Mayo now anticipates that the company will earn ($0.08) per share for the quarter, down from their prior forecast of ($0.07). The consensus estimate for Alignment Healthcare's current full-year earnings is ($0.69) per share. Leerink Partnrs also issued estimates for Alignment Healthcare's Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.20) EPS, Q1 2026 earnings at $0.03 EPS, Q2 2026 earnings at $0.20 EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at ($0.09) EPS, FY2028 earnings at $0.78 EPS and FY2029 earnings at $1.28 EPS.

ALHC has been the subject of a number of other research reports. Wall Street Zen upgraded shares of Alignment Healthcare from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Robert W. Baird boosted their price objective on shares of Alignment Healthcare from $17.00 to $22.00 and gave the company an "outperform" rating in a research report on Tuesday, April 15th. Barclays raised shares of Alignment Healthcare from an "underweight" rating to an "equal weight" rating and boosted their price objective for the company from $9.00 to $13.00 in a report on Thursday, July 31st. Stephens raised Alignment Healthcare to a "strong-buy" rating in a research note on Monday, June 2nd. Finally, UBS Group lifted their price target on Alignment Healthcare from $16.00 to $17.00 and gave the stock a "neutral" rating in a report on Friday, May 2nd. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Alignment Healthcare currently has a consensus rating of "Moderate Buy" and a consensus price target of $18.56.

Alignment Healthcare Price Performance

Shares of NASDAQ:ALHC traded down $0.19 on Monday, reaching $13.52. 1,140,350 shares of the company were exchanged, compared to its average volume of 3,012,939. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 2.29. Alignment Healthcare has a 1-year low of $8.17 and a 1-year high of $21.06. The firm has a market cap of $2.68 billion, a price-to-earnings ratio of -47.91 and a beta of 1.16. The company has a 50-day moving average of $13.82 and a 200-day moving average of $15.31.

Alignment Healthcare (NASDAQ:ALHC - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.14. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $960.25 million. Alignment Healthcare had a negative return on equity of 43.68% and a negative net margin of 1.53%. The business's quarterly revenue was up 49.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.13) EPS.

Insiders Place Their Bets

In related news, CEO John E. Kao sold 180,000 shares of the business's stock in a transaction that occurred on Thursday, July 10th. The stock was sold at an average price of $13.41, for a total value of $2,413,800.00. Following the completion of the sale, the chief executive officer owned 1,553,100 shares in the company, valued at $20,827,071. The trade was a 10.39% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, President Dawn Christine Maroney sold 30,000 shares of the firm's stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $13.44, for a total transaction of $403,200.00. Following the completion of the sale, the president owned 2,042,899 shares of the company's stock, valued at $27,456,562.56. This trade represents a 1.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 17,700,753 shares of company stock valued at $269,911,757 over the last 90 days. 7.00% of the stock is owned by insiders.

Institutional Trading of Alignment Healthcare

Several large investors have recently added to or reduced their stakes in ALHC. Wellington Management Group LLP increased its stake in shares of Alignment Healthcare by 77.9% in the 4th quarter. Wellington Management Group LLP now owns 7,438,500 shares of the company's stock worth $83,683,000 after acquiring an additional 3,257,630 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in Alignment Healthcare by 54.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 8,649,042 shares of the company's stock valued at $97,302,000 after buying an additional 3,059,596 shares during the last quarter. Millennium Management LLC raised its holdings in Alignment Healthcare by 588.3% during the fourth quarter. Millennium Management LLC now owns 3,388,602 shares of the company's stock worth $38,122,000 after purchasing an additional 2,896,311 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Alignment Healthcare during the fourth quarter valued at $20,087,000. Finally, Invesco Ltd. boosted its holdings in shares of Alignment Healthcare by 1,415.7% in the 1st quarter. Invesco Ltd. now owns 1,875,790 shares of the company's stock valued at $34,927,000 after purchasing an additional 1,752,033 shares during the last quarter. Hedge funds and other institutional investors own 86.19% of the company's stock.

About Alignment Healthcare

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.